Valsartan/amlodipine single pill combination for the treatment of hypertension

References

• Patricia M, Kearney PM, Whelton M et al. Global burden of hypertension: analysis of worldwide data. Lancet365, 217–223 (2005).
   Google Scholar
• Chobanian AV, Bakris GL, Black HR et al; and the National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA289, 2560–2572 (2003).
   PubMed Web of Science ®Google Scholar
• Cutler JA, Sorlie PD, Wolz M, Thom T, Fields LE, Roccella EJ. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988–1994 and 1999–2004. Hypertension52, 818–827 (2008).
   PubMed Web of Science ®Google Scholar
• Wolf-Maier K, Cooper RS, Kramer H et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension43, 10–17 (2004).
   PubMed Web of Science ®Google Scholar
• Okonofua EC, Simpson KN, Jesri A, Rehman SU, Durkalski VL, Egan BM. Therapeutic inertia is an impediment to achieving the healthy people 2010 blood pressure control goals. Hypertension.47, 345–351 (2006).
   PubMed Web of Science ®Google Scholar
• Chapman RH, Benner JS, Petrilla AA et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch. Int. Med.165, 1147–1152 (2005).
   PubMed Web of Science ®Google Scholar
• Berg JS, Dischler J, Wagner DJ, Raia JJ, Palmer-Shevlin N. Medication compliance: a healthcare problem. Ann. Pharmacother.27(Suppl.), 1–24 (1993).
   PubMed Web of Science ®Google Scholar
• Métry J-M. Drug Regimen Compliance: Issues in Clinical Trials and Patient Management. John Wiley & Son Ltd, NJ, USA (1999).
   Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. N. Engl. J. Med.353, 487–497 (2005).
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Sever PS, Poulter NR et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet366, 895–906 (2005).
   PubMed Web of Science ®Google Scholar
• Bakris GL. The importance of blood pressure control in the patient with diabetes. Am. J. Med.116, 30S–38S (2004).
   PubMed Web of Science ®Google Scholar
• The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 Guidelines for the Management of Arterial Hypertension. J. Hypertens.25, 1105–1187, 2007
   PubMed Web of Science ®Google Scholar
• Mancia G, Laurent S, Agabiti-Rosei E et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J. Hypertens.27, 2121–2158 (2009).
   PubMed Web of Science ®Google Scholar
• Jamerson K, Weber MA, Bakris GL et al; for the ACCOMPLISH trial investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med.359, 2417–2428 (2008).
   PubMed Web of Science ®Google Scholar
• Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am. J. Geriatr. Pharmacother.5, 345–351 (2007).
   PubMedGoogle Scholar
• Dezii CM. A retrospective study of persistence with single-pill combination therapy vs concurrent two-pill therapy in patients with hypertension. Manag. Care9(Suppl.), 2–6 (2000).
   PubMedGoogle Scholar
• Brixner DI, Jackson KC 2nd, Sheng X, Nelson RE, Keskinaslan A. Assessment of adherence, persistence, and costs among valsartan and hydrochlorothiazide retrospective cohorts in free-and fixed-dose combinations. Curr. Med. Res. Opin.24, 2597–607 (2008).
   PubMed Web of Science ®Google Scholar
• Blonde L, Wogen J, Kreilick C, Seymour AA. Greater reductions in A1C in Type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co-administered with metformin. Diabetes Obes. Metab.5, 424–431 (2003).
   PubMed Web of Science ®Google Scholar
• Düsing R. Optimizing blood pressure control through the use of fixed combinations. Vasc. Health Risk Manag.6, 321–325 (2010).
   PubMedGoogle Scholar
• Diovan (valsartan) tablets [prescribing information]. Novartis Pharmaceuticals Corporation, NJ, USA (2008).
   Google Scholar
• Norvasc (amlodipine) tablets [prescribing information]. Pfizer Labs, Division of Pfizer Inc., NY, USA (2006).
   Google Scholar
• Philipp T, Smith TR, Glazer R et al. Two multicenter, 8 week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin. Ther.29, 563–580 (2007).
   PubMed Web of Science ®Google Scholar
• Philipp T, Glazer RD, Zhao Y, Pospiech R. Long-term tolerability and efficacy of the combination of amlodipine/valsartan in hypertensive patients: a 54-week, open-label extension study. Curr. Med. Res. Opin.25, 187–193 (2009).
   PubMed Web of Science ®Google Scholar
• Smith TR, Philipp T, Vaisse B et al. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. J. Clin. Hypertens. (Greenwich)5, 355–364 (2007).
   Google Scholar
• Destro M, Luckow A, Samson M, Kandra A, Brunel P. Efficacy and safety of amlodipine/valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: a randomized, double-blind, multicenter study: the EX-EFFeCTS study. J. Am. Soc. Hypertens.2, 294–302 (2008).
   PubMed Web of Science ®Google Scholar
• Schunkert H, Glazer RD, Wernsing M et al. Efficacy and tolerability of amlodipine/valsartan combination therapy in hypertensive patients not adequately controlled on amlodipine monotherapy. Curr. Med. Res. Opin.25, 2655–2662 (2009).
   PubMed Web of Science ®Google Scholar
• Flack JM, Calhoun DA, Satlin L, Barbier M, Hilkert R, Brunel P. Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: the EX-STAND study. J. Hum. Hypertens.23, 479–489 (2009).
   PubMed Web of Science ®Google Scholar
• Alleman Y, Fraile B, Lambert M, Barbier M, Ferber P, Izzo JL Jr. Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in failure after single therapy (EX-FAST) study. J. Clin. Hypertens.10, 185–194 (2008).
   Web of Science ®Google Scholar
• Messerli FH, Oparil S, Feng Z. Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension. Am. J. Cardiol.86, 1182–1187 (2000).
   PubMed Web of Science ®Google Scholar
• Messerli FH. Vasodilatory edema: a common side effect of antihypertensive therapy. Curr. Cardiol. Rep.6, 479–482 (2002).
   Google Scholar
• Fogari R, Zoppi A, Derosa G et al. Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J. Hum. Hypertens.21, 220–224 (2007).
   PubMed Web of Science ®Google Scholar
• Frech-Tamas FH, Zhang W, Dastani HB, Gause D. Patient compliance with single pill, dual and triple antihypertensive combinations. Circulation120, 522 (2009) (Abstract).
   Google Scholar